Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient

Published:2021-01-18 Issue:5 Volume:32 Page:580-584
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Cabezas-Camarero Santiago,Cabrera-Martin Maria Nieves,Saiz-Pardo Sanz Melchor,Perez-Segura Pedro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference26 articles.

1. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.;Ferris;N Engl J Med,2016

2. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.;Cohen;Lancet,2019

3. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.;Zandberg;Eur J Cancer,2019

4. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.;Ferris;Ann Oncol,2020

5. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial.;Siu;JAMA Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and preliminary activity of pembrolizumab‑carboplatin‑paclitaxel in heavily pretreated and/or fragile patients with PDL1‑positive recurrent/metastatic head and neck cancer;Oncology Letters;2022-12-07

2. Chemotherapeutic Protocols for the Treatment of Head and Neck Cancer;Chemotherapy Protocols and Infusion Sequence;2022

3. Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer;Oral Oncology;2021-12

4. Carboplatin/paclitaxel/pembrolizumab;Reactions Weekly;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3